The ongoing COVID-19 pandemic—and the worldwide reaction to it—has compelled companies to radically rethink their strategies and the way they operate. We salute the industry experts helping companies survive and sustain in this pandemic.
At MarketsandMarkets™, analysts are undertaking continuous efforts to provide analysis of the COVID-19 impact on the PDX Models Market. We are working diligently to help companies take rapid decisions by studying:
1. The impact of COVID-19 on the PDX Models Market, including growth/decline in product type/use cases due to the cascaded impact of COVID-19 on the extended ecosystem of the market.
2. The rapid shifts in the strategies of the Top 50 companies in the PDX Models Market
3. The shifting short-term priorities of the top 50 companies’ clients and their client’s clients
You can request an in-depth analysis detailing the impact of COVID-19 on the PDX Models Market:
According to the recent report “Patient Derived Xenograft/PDX Models Market by Type (Mouse & Rat), Tumor Type (Gastrointestinal, Gynecological, Respiratory), Application (Pre-Clinical Drug Development & Biomarker Analysis), End User (Pharma & Biotech, CRO) – Global Forecast to 2022″, The PDX models market is expected to reach USD 167.6 Million by 2022 from an estimated USD 77.4 Million in 2017, at a CAGR of 16.7%.
Browse in-depth TOC on “PDX Models Market”
44 – Tables
34 – Figures
148 – Pages
Download PDF Brochure:
The key factors driving the growth of this market include the growing demand for personalized medicine, continuous support for cancer research from the public as well as private sectors, and growth in the number of R&D activities in the pharmaceutical industry. The growing use of humanized PDX models is posing a lucrative opportunity in this market.
By tumor type, the gastrointestinal tumor models segment accounted for the largest share of the market in 2017
On the basis of tumor type, the PDX models market has been segmented into gastrointestinal tumor models, gynecological tumor models, respiratory tumor models, urological tumor models, hematological tumor models, and other tumor models such as head & neck tumors, sarcoma, and melanoma. In 2017, the gastrointestinal tumors segment is expected to account for the largest share of the global PDX models market.
By application, the preclinical drug development and basic cancer research held the largest market share in 2017
Based on application, the PDX models market is further segmented into the preclinical drug development & basic cancer research and biomarker analysis. In 2017, the preclinical drug development and basic cancer research segment is expected to account for the largest share of the global PDX models market. The large share of this segment can be mainly attributed to the increasing number of research activities in the field of oncology drug research.
Geographical Growth Analysis:
North America accounted for the largest share of the PDx models market in 2017, followed by Europe. The large share of the North American PDX models market can be attributed to the growth in biomedical research in the US, rising preclinical activities by CROs and pharmaceutical companies, and growing stem cell research in Canada. However, the Asia Pacific market is projected to grow at the highest CAGR.
Request Sample Pages:
The various players in the PDX models market include Crown Bioscience Inc. (US), WuXi AppTec (China), Champions Oncology, Inc. (US), The Jackson Laboratory (US), ONCODESIGN (France), Charles River Laboratories International, Inc. (US), EPO Berlin-Buch GmBH (Germany), Shanghai LIDE Biotech Co., Ltd. (China), Xentech (France), Horizon Discovery Group PLC (UK), Urolead (France), and Explora BioLabs (US).